Viral Vaccine Vectors in Personalized Medicine

Projektinformationen

VIVAVE

ID Finanzhilfevereinbarung: 737592

DOI

10.3030/737592

Projekt abgeschlossen

EK-Unterschriftsdatum 27 Januar 2017

Startdatum 1 Februar 2017

Enddatum 31 Dezember 2018

Finanziert unter

• EXCELLENT SCIENCE - European Research Council (ERC)

Gesamtkosten

€ 149 858,00

EU-Beitrag

€ 149 858,00

Koordiniert durch

HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH
Germany

Periodic Reporting for period 1 - VIVAVE (Viral Vaccine Vectors in Personalized Medicine)

Berichtszeitraum: 2017-02-01 bis 2018-12-31

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

VIVAVE provided us with initial and vital information on the ability of a novel class of vaccine vectors. We have tested a vector that infects numerous types of human cells and expresses antigens in them, allowing recognition by CD8 T cells and their activation, but which due to its natural properties does not propagate itself in human cells. The vector was tested in several human cell and in coculture with human T cells. Testing of the vector in preclinical animal models will be continued through additional public funding, which was secured based on results from this the ERC PoC.